the clearance of driver mutations following allosct impacts myelofibrosis disease outcomes
Published 9 months ago • 99 plays • Length 2:07Download video MP4
Download video MP3
Similar videos
-
2:10
the impact of sf3b1 mutation in myelofibrosis
-
4:50
timing of driver mutations and clonal dynamics in mpns: a new paradigm for blood cancer development
-
1:33
outcomes of reduced intensity allosct in patients with accelerated-phase myelofibrosis
-
1:32
genomic sequencing as a driver of advancements in pediatric hematology
-
3:07
the impact of blast enumeration & co-occurring myelodysplasia-related mutations in npm1-mutated aml
-
3:35
analysis from most: disease progression and leukemic transformation in lower-risk myelofibrosis
-
1:13
the current bsh guidelines for the diagnosis and evaluation of prognosis of myelofibrosis
-
2:07
analysis of long-term exposure to momelotinib in the phase iii simplfy myelofibrosis trials
-
4:09
myelofibrosis (rare blood cancer): what are the first symptoms? | the patient story
-
37:45
women's leadership summit on the business of social media panel discussion
-
13:13
precision medicine in myeloproliferative neoplasms
-
1:31
promising agents under investigation for the treatment of myelofibrosis with cytopenia
-
3:08
sf3b1 mutation and atm deletion co-drive leukemogenesis through centromeric r-loop dysregulation
-
1:15
exploring the evolving treatment landscape of myelofibrosis
-
2:06
an insight into the challenges and management of myeloproliferative neoplasm-unclassifiable (mpn-u)
-
4:16
jak inhibitor selection & sequencing in myelofibrosis
-
24:37
current management of myelofibrosis - ronald hoffman, md
-
1:26
incidence and risk factors associated with vod/sos in younger vs older adults after sct
-
1:16
indirect comparison of the safety of momelotinib vs fedratinib in patients with myelofibrosis
-
3:31
post-induction undetectable mrd ameliorates the high risk determined by fish among ndmm
-
1:33
quantifying mutant myd88 expression to track disease burden in wm
-
1:01
exploring the biological mechanisms driving mbl progression to cll